Trulieve Cannabis (TRLV) EBIT (2020 - 2026)

Trulieve Cannabis has reported EBIT for 7 years, with the latest figure at -$370.5 million in Q2 2026.

• On a quarterly basis, EBIT fell 803.96% year-over-year to -$370.5 million in Q2 2026; TTM through Jun 2026 was -$277.3 million, a 415.48% decrease from a year earlier, with the FY2025 full-year figure at $143.5 million, up 46.75% from the prior year.
• EBIT was -$370.5 million for Q2 2026 at Trulieve Cannabis, down from $35.7 million in the prior quarter.
• The five-year high for EBIT was $52.6 million in Q2 2025, with the low at -$370.5 million in Q2 2026.
• Average EBIT over 5 years is -$14.8 million, with a median of $26.3 million recorded in 2022.
• The sharpest annual moves came in 2025 and 2026: EBIT soared 6734.63% in 2025, then sank 803.96% in 2026.
• Over 5 years, EBIT stood at $5.2 million in 2022, then jumped by 460.51% to $29.2 million in 2023, then slumped by 95.52% to $1.3 million in 2024, then jumped by 1069.5% to $15.3 million in 2025, then slumped by 2522.19% to -$370.5 million in 2026.
• The last three EBIT figures came in at -$370.5 million (Q2 2026), $35.7 million (Q1 2026), and $15.3 million (Q4 2025), per Business Quant data.